Inflammatory Disease Biotechnology Company Invea Therapeutics (INAI.US) withdraws $35 million IPO plan.

14:29 09/03/2026

Biotechnology company Invea Therapeutics (INAI.US), which is developing oral small molecule drugs for inflammatory diseases, withdrew its initial public offering plan for its US stock last Friday, citing market conditions.

Biotechnology company Invea Therapeutics (INAI.US) developing oral small molecule drugs for inflammatory diseases withdrew its US IPO plan last Friday citing market conditions. The company had previously filed to offer 3.2 million shares at a price range of $10 to $12 per share, aiming to raise $35 million. Headquartered in Guilford, Connecticut, this company was founded in 2021 and planned to list on Nasdaq under the ticker symbol INAI. ThinkEquity was set to be the exclusive bookrunner for the transaction.

Industrial: How do high oil prices affect US inflation and Federal Reserve actions?

EB SECURITIES: AI inflation is giving birth to a new cycle, and the price increase of optical fiber and copper-clad laminate is driving the growth of industry companies.

Microsoft Corporation (MSFT.US) Azure takes the lead and becomes the first global cloud service provider to begin validating the NVIDIA Corporation Vera Rubin NVL72 system.

Industrial: How do high oil prices affect US inflation and Federal Reserve actions?

EB SECURITIES: AI inflation is giving birth to a new cycle, and the price increase of optical fiber and copper-clad laminate is driving the growth of industry companies.

Microsoft Corporation (MSFT.US) Azure takes the lead and becomes the first global cloud service provider to begin validating the NVIDIA Corporation Vera Rubin NVL72 system.